Comparisons of iv Ibuprofen and iv Paracetamol During Bariatric Surgery

Comparisons of iv Ibuprofen and iv Paracetamol for Postoperative Pain Levels and Opioid Consumption During Bariatric Surgery

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT02778958

Enrollment

Registered

2016-05-20

Start date

2016-01-31

Completion date

2017-03-31

Last updated

2018-03-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Bariatric Surgery Candidate, Obesity, Morbid

Keywords

bariatric surgery, morbid obesity, nonopioid analgesics

Brief summary

The aim of this study is to evaluate and to compare the effectiveness of iv ibuprofen and iv paracetamol during bariatric surgery.

Detailed description

Evaluation of effectiveness of iv ibuprofen and iv paracetamol on postoperative pain, opioid consumption, and side effects in morbidly obese patients undergoing bariatric laparoscopic surgery

Interventions

DRUGparacetamol

iv paracetamol flakon, 1 gram infusion at 30 min; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)

DRUGibuprofen

iv ibuprofen flakon, 800 mg; iv morphine with patient controlled analgesia (1 mg demand bolus dose, 20 min lockout time)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

QUADRUPLE (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Inclusion criteria

* Patients undergoing laparoscopic sleeve gastrectomy and gastric by-pass surgery

Exclusion criteria

* Hepatic disfunction, * Renal failure (creatinine \> 3 mg/dL,creatinin clearance \< 60 mL/dk or urine out-put \< 500 mL/day ) or a history of dialysis 28 days before surgery, * A history of gastrointestinal bleeding or bleeding diathesis 6 weeks before surgery, therapeutic dose of anticoagulation therapy (except subcutaneous heparin prophylactic dose), * Angiotensin converting enzymes inhibitor or antihypertensive combination with furosemide, * A history of opioid addiction or opioid tolerance * Allergy to study drugs, * Noncooperative patients for pain assessments

Design outcomes

Primary

Measure	Time frame	Description
Opioid (morphine) consumption	First 24 hours during postoperative period	iv morphine patient controlled analgesia for multimodal analgesia

Secondary

Measure	Time frame	Description
Postoperative pain level	First 24 hours during postoperative period	Visual analog scale for evaluation of postoperative pain levels

Other

Measure	Time frame	Description
Side effects	First 24 hours during postoperative period	Side effects of study drugs and opioids

Countries

Turkey (Türkiye)

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026